Pfizer’s Lyrica: DEA Proposes Schedule V Designation, Comments Due June 13

The pregabalin launch is at least a month away following the Drug Enforcement Administration’s proposed rule on controlled substance scheduling for the neuropathic pain agent. Lyrica has a “low potential for abuse” relative to Schedule IV substances, DEA says.